Management of herpes zoster and post-herpetic neuralgia now and in the future

J Clin Virol. 2010 May:48 Suppl 1:S20-8. doi: 10.1016/S1386-6532(10)70005-6.


Herpes zoster (HZ; shingles)--a reactivation of the latent varicella zoster virus (VZV)--can cause significant morbidity. Its major complication is pain, particularly post-herpetic neuralgia (PHN). We will review the current management strategies available for the treatment of both acute HZ and PHN, including antiviral drugs, analgesic agents, anticonvulsants, tricyclic antidepressants and topical therapies. New molecules in development that show improved activity against VZV are also covered, and new drug targets are outlined. The role of translational neuroscience in moving towards a goal of finding disease-modifying treatments will be examined.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Analgesics / therapeutic use
  • Anticonvulsants / therapeutic use
  • Antidepressive Agents, Tricyclic / therapeutic use
  • Antiviral Agents / therapeutic use
  • Clinical Trials as Topic
  • Herpes Zoster / complications
  • Herpes Zoster / drug therapy*
  • Herpes Zoster / therapy
  • Herpesvirus 3, Human / drug effects
  • Humans
  • Neuralgia, Postherpetic / drug therapy*
  • Neuralgia, Postherpetic / etiology
  • Treatment Outcome


  • Analgesics
  • Anticonvulsants
  • Antidepressive Agents, Tricyclic
  • Antiviral Agents